US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...
Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSEâ„¢ Pulsed Field Ablation ...
Atrial fibrillation is the most common arrhythmic ... it is imperative for the clinician to be informed about these arrhythmias and treatment considerations. This paper presents a basic review ...
Cite this: Progress in Paroxysmal Nocturnal Hemoglobinuria Treatment: The Impact of New Data From ASH 2024 - Medscape - Jan 02, 2025. Professor of Clinical Medicine, Jane Anne Nohl Division ...
We report the individual components of MACE+ and the individual rhythm disturbances contributing to the composite arrhythmia end point (ie, atrial fibrillation and other arrhythmias including ...
SEATTLE, Dec. 6, 2024 /PRNewswire/ -- The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive ...
In particular, the patients had recurrent episodes of paroxysmal atrial fibrillation ... ectopic atrial tachycardia from a single pulmonary vein. There were no serious complications in either group, ...
7 Rate control in combination with anticoagulation as front-line treatment has been shown ... Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med.